Results 51 to 60 of about 9,659 (276)

Low-Molecular Weight Inhibitors of Galectins

open access: yes, 2012
The galectins are known to be able to recognize and cross-link beta-D-galactopyranoside-containing glycoconjugates as a result of presenting multiple binding sites.
Nilsson, Ulf,   +2 more
core   +1 more source

The Galectins as Targets for Cancer Therapeutics [PDF]

open access: yes, 2013
The galectins are the most ancient and widely expressed family of glycan-binding protein, and have been found in all metazoans examined to date. Galectins recognise and bind to carbohydrate ligands, specifically those that contain [beta]-galactosides ...
Collins, Patrick
core   +1 more source

Galectins in Protozoan Parasitic Diseases: Potential Applications in Diagnostics and Therapeutics

open access: yesCells, 2023
Neglected tropical diseases (NTDs) constitute a group of diseases that generally develop in tropical or subtropical climatic conditions and are related to poverty.
Cássio Meira   +8 more
doaj   +1 more source

Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma

open access: yesLiver Research, 2020
Galectins (Gals) are evolutionarily conserved proteins that bind to β-galactoside containing glycans. Abnormal expression of Gals is associated with the development, progression, and metastasis of different types of cancer. Among the 11 Gals identified in humans, the roles of Gal-1 and Gal-3 have been extensively investigated in various tumors.
Setayesh, Tahereh   +2 more
openaire   +5 more sources

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

open access: yesArthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos   +2 more
wiley   +1 more source

3D Bioprinted Glioblastoma Multiforme Models: How the Extracellular Matrix Glycosignature Influences Drug Response

open access: yesAdvanced Functional Materials, EarlyView.
Aberrant glycosylation in the glioblastoma tumor microenvironment drives therapeutic resistance. Here, a 3D bioprinted model was engineered by incorporating α‐NeuNAc‐(2→3)‐β‐D‐Gal‐ and chondroitin sulfate. Combined multiplex immunofluorescence and synchrotron‐based nanoCT analysis revealed that glycan‐matrix interactions dictate specific drug‐escape ...
Francesca Cadamuro   +25 more
wiley   +1 more source

The Emerging Role of Galectins and O-GlcNAc Homeostasis in Processes of Cellular Differentiation

open access: yesCells, 2020
Galectins are a family of soluble β-galactoside-binding proteins with diverse glycan-dependent and glycan-independent functions outside and inside the cell.
Rada Tazhitdinova   +1 more
doaj   +1 more source

Galectin-1 for Neuroprotection? [PDF]

open access: yesImmunity, 2012
Classically activated microglia (M1) are believed to play a key role in neuronal degeneration in multiple sclerosis (MS). In this issue of Immunity, Starossom et al. (2012) show that Galectin-1 exerts a neuroprotective function through glycosylation-dependent inactivation with M1 cells.
Nonaka, Motohiro, Fukuda, Minoru
openaire   +2 more sources

Ionizable Lipid‐Dependent Optimization of Steroid Lipid Nanoparticles With Tunable Immunomodulatory Properties

open access: yesAdvanced Materials, EarlyView.
A novel engineering strategy that establishes material design principles for incorporating anti‐inflammatory steroids into lipid nanoparticles to reduce LNP‐induced inflammation while retaining mRNA delivery. Results are validated in vitro and in three animal models of inflammation and autoimmunity in vivo.
Ajay S. Thatte   +21 more
wiley   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

open access: yesAdvanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy